Leishmaniasis vaccines: past, present and future.
No vaccine exists against any form of leishmaniasis. Because recovery from infection is usually accompanied by a strong immunity and because it is possible to protect experimental animals against live challenge, hope for the development of a vaccine for humans has been high. However, leishmaniasis is a disease of the poor and the market for a vaccine is very limited. Until a few years ago, with minimal resources, only a pragmatic approach was possible for testing the first-generation vaccines (i.e. killed whole parasites). Recently, funding has become available for developing defined second-generation vaccines, including recombinant proteins and DNA constructs. With new adjuvants also being developed there is new hope, and several new vaccines are in development against leishmaniasis.
Modabber
Farrokh
F
Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland. fmodabber@dndi.org
D000818:Animals; D055808:Drug Discovery / Q000191:economics / Q000639:trends*; D006801:Humans; D007896:Leishmaniasis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D054332:Leishmaniasis Vaccines / Q000191:economics / Q000276:immunology*; D015047:Zoonoses / Q000453:epidemiology*
D054332:Leishmaniasis Vaccines